USS Investment Management’s Neurocrine Biosciences NBIX Stock Holding History

USS Investment Management’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.83M	Buy	+16,800	New	+$2.49M	0.01%	475
2022 Q3	–	Sell	-7,018	Closed	-$684K	–	665
2022 Q2	$684K	Sell	7,018 -1,368	-16%	-$126K	0.01%	643
2022 Q1	$787K	Sell	8,386 -12,361	-60%	-$1.05M	0.01%	672
2021 Q4	$1.77M	Hold	20,747	–	–	0.01%	648
2021 Q3	$1.99M	Buy	20,747 +15,312	+282%	+$1.45M	0.02%	627
2021 Q2	$529K	Hold	5,435	–	–	﹤0.01%	584
2021 Q1	$529K	Hold	5,435	–	–	﹤0.01%	572
2020 Q4	$521K	Hold	5,435	–	–	﹤0.01%	562
2020 Q3	$523K	Hold	5,435	–	–	0.01%	545
2020 Q2	$663K	Buy	+5,435	New	+$601K	0.01%	517

Other funds holding NBIX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

USS Investment Management's NBIX Position: Q2 2026 in Review

USS Investment Management opened a new position in Neurocrine Biosciences (NBIX) in Q2 2026: 16,800 shares worth $2.83M. The stake represents 0.01% of the portfolio and ranks #475 among its holdings. This is a return to the name: USS Investment Management previously reported a position in NBIX as recently as Q2 2022.

USS Investment Management first reported a position in NBIX in Q2 2020 and has held it in 10 quarters since. 781 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

USS Investment Management held 16,800 shares of Neurocrine Biosciences worth $2.83M as of Q2 2026.
Neurocrine Biosciences was a new USS Investment Management position in Q2 2026.
Neurocrine Biosciences made up 0.01% of USS Investment Management's portfolio in Q2 2026, its #475 holding.
USS Investment Management first reported a position in Neurocrine Biosciences in Q2 2020 and has held it in 10 quarters since.
781 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on USS Investment Management's 13F filing for Q2 2026, filed 11 Aug 2026.